Figure 6:

Circulating PD-L1⁺ EVs can be used as follow-up markers in SCLC patients. Case study of the correlation between EV PD-L1 levels in plasma samples from SCLC patients and response to therapy. Concomitant imaging and EV PD-L1 sampling in three patients experiencing (A) response as observed in the hilar on CT scan; (B) tumor metastases to the brain by MRI scan; (C) initial response (at cure 1) then disease progression as detected in the hilar and pleura on CT scan. R: response, PD: progression of the disease. Tumor sites in the scans are indicated by a red arrow.